IBA Secures $60M+ Deal for 12 Cyclone KIUBE Systems in US Radiopharmaceutical Expansion
Event summary
- IBA SA wins contract for 12 Cyclone® KIUBE 300 systems (€2.5M–€5M each) from an unnamed global radiopharmaceutical producer.
- Systems will form a national PET radiopharmaceutical production network across multiple US sites.
- Order includes Nirta® HCFT 18F helium cooling free targets, IntegraLab® facility design, and operator training.
- Deployment aims to secure capacity ahead of demand for diagnostic and therapeutic radiopharmaceuticals.
- IBA claims Cyclone® KIUBE 300 can produce up to 35 Ci of 18F in a single two-hour dual beam run.
The big picture
This deal underscores the growing industrial capacity constraints in radiopharmaceutical production, particularly in the US market. The strategic move to secure capacity ahead of demand reflects broader industry trends where supply chain and production infrastructure dictate the pace of innovation in diagnostics and theranostics. IBA's ability to execute at scale positions it as a critical enabler for the next wave of radiopharmaceutical advancements.
What we're watching
- Capacity Utilization
- Whether the secured capacity will be fully utilized as therapeutic radiopharmaceutical pipelines mature.
- Competitive Positioning
- How this deal strengthens IBA's dominance in high-output cyclotron technology against competitors.
- Regulatory Dynamics
- The pace at which US regulatory approvals for new radiopharmaceuticals could drive demand for IBA's systems.
Related topics